This report examines trends and sales in the global market for nasal vaccines through 2027. Leaders in the industry and their vaccine portfolios, the need for nasal vaccine development, competitive intelligence and regional trends are discussed. The report includes a PESTEL analysis, that forms in part the base data for qualitative analysis and market estimates.
The report examines all forms of nasal vaccines, such as nasal drops or sprays, but excludes intramuscular and oral vaccines. The report discusses nasal vaccines by type, such as live-attenuated, inactivated, protein subunit and viral vectors. The application areas covered include pediatric and adult. Primary care clinics, hospitals, pharmacies and others are the end-user segments covered.
Report Includes
- 23 data tables and 27 additional tables
- A comprehensive overview and up-to-date analysis of the global market for nasal vaccines
- Analyses of the global market trends, with historic market revenue data (sales figures) for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the upcoming market opportunities and trends driving and restricting growth of the global nasal vaccines market and its sub-segments, and the major regions and countries involved in market developments
- Estimation of the actual market size and revenue forecast for the global nasal vaccines market in USD millions, and its corresponding market share analysis by vaccine type, dosage form, patient group, end-user, and region
- Discussion of new developments in the nasal vaccines market, underlying clinical trials for all phases and list of vaccines, and their regulatory approvals etc.
- Identification of the major stakeholders and analysis of the competitive landscape based on recent developments, financial performance, and segmental revenues
- Review of the new announcements, approvals, FDA clearances, partnerships and collaborations in the global nasal vaccines market
- Detailed company profiles of the leading industry players, including AstraZeneca plc, BioDiem Ltd., BlueWillow Biologics, Meissa Vaccines Inc., and Serum Institute of India Pvt., Ltd.
Table of Contents
Samples
LOADING...
Executive Summary
In the wake of the COVID-19 pandemic, Nasal vaccines are experiencing increased demand. Leading manufacturers in the vaccine industry are eyeing nasal vaccines as future revenue producers. This can be attributed to increasing government and regulatory support, which has also led to the rapid development of effective intramuscular COVID vaccines. The emergence of coronavirus variants that can evade the immune response generated by existing vaccines has encouraged the research community and vaccine manufacturers to develop nasal vaccines that can be delivered as spray or drops into the nose and provide additional protection by stimulating mucosal immunity.
Nasal vaccines are anticipated to be a major game changer in blocking the transmission of diseases such as COVID-19. For instance, Indian vaccine manufacturer Bharat Biotech’s intranasally administered COVID vaccine ais in Phase 3 clinical trials. The vaccine also received emergency use authorization (EUA) by the Indian Drug Authority in September 2022. AstraZeneca’s nasal spray flu vaccine is used globally in children and adults. In Russia, the Gamaleya institute has developed the Sputnik nasal vaccine for adults and is currently being tested on children between the ages of 8 and 12, and so far, has shown no side effects.
Nasal vaccines have certain advantages over the mainstay vaccines. In the present situation of waning and waxing COVID waves due to new variants, the medical profession needs noninvasive and less expensive alternatives to injectable vaccines. Nasal vaccines achieve both: They eliminate the use of needles, thus reducing the cost of vaccines and facilitating mass vaccination. They also may increase vaccination compliance among individuals who are afraid of syringes. Because they can be delivered in spray form, nasal vaccines avoid the possibility of needle contamination. They are more cost-effective for low- and middle-income countries because the storage conditions required for these vaccines are
less complicated than the cold storage facilities required for intramuscular vaccines. Moreover, nasal vaccines are more effective against respiratory viruses, as they induce antibody production in the airway passages. Finally, nasal vaccines can be self-administered, relieving some of the pressure on overworked healthcare professionals. For viruses such as SARS-CoV-2 that can mutate rapidly, nasal vaccines are the best option as their spike proteins can be easily replaced to combat new versions of a virus.
The coordination between researchers, industrial resources, government support and conducive market forces will further propel the nasal vaccine market in the coming years. Researchers are optimistic about developing nasal vaccines to control the spread of the next pandemic, whether from COVID or another respiratory virus. This would be unlike coronavirus vaccines, where it is difficult to identify the vaccinated asymptomatic carriers and therefore cannot block the virus transmission chain. However, the market is in dire need of the substantial funding required to accelerate the development of nasal vaccines.
Companies Mentioned
- Astrazeneca plc
- Bharat Biotech International Ltd.
- Biodiem Ltd.
- Bluewillow Biologics Inc.
- Codagenix Inc.
- Changchun Bcht Biotechnology Co.
- Cyanvac LLC
- Intravacc LLC
- Meissa Vaccines Inc.
- Razi Vaccine and Serum Research Institute
- Serum Institute of India Pvt. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 78 |
| Published | December 2022 |
| Forecast Period | 2022 - 2027 |
| Estimated Market Value ( USD | $ 383.8 Million |
| Forecasted Market Value ( USD | $ 568.1 Million |
| Compound Annual Growth Rate | 8.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
